Joanna Niemiec

Joanna Niemiec

Auto-generated profile, based on publicly available information

Joanna Niemiec

Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2016 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
EŁElżbieta Łuczyńska
Elżbieta Łuczyńska
JNJoanna Niemiec
Joanna Niemiec
EHEdward Hendrick
Edward Hendrick
SHSylwia Heinze
Sylwia Heinze
JJJanusz Jaszczyński
Janusz Jaszczyński
JRJanusz Rys
Janusz Rys
BACKGROUND:Contrast enhanced spectral mammography (CESM) is a new method of breast cancer diagnosis in which an iodinated contrast agent is injected and dual-energy mammography is obtained in multiple views of the breasts. The aim of this study was t...

14 May 2019 in European Radiology
Verified
Journal Article
Open access
PDF file
Wojciech RudnickiWojciech Rudnicki
Wojciech Rudnicki
SHSylwia Heinze
Sylwia Heinze
JNJoanna Niemiec
Joanna Niemiec
ZKZbigniew Kojs
Zbigniew Kojs
BSBeata Sas-Korczyńska
Beata Sas-Korczyńska
EŁElżbieta Łuczyńska
Elżbieta Łuczyńska
Objectives Contrast-enhanced spectral mammography (CESM) is a novel method for breast cancer detection. The aim of this study is to check if there is a possibility of quantitative assessment of contrast enhancement in CESM and if there is any correlation between quantitative assessment of contrast enhancement in CESM and histopathology. Methods A total of 167 female patients underwent CESM. All subjects previously had suspicious lesions found on mammography, breast ultrasound, or both. After imaging, the following parameters were evaluated: number of enhancing lesions in each breast and size and degree of enhancement of each lesion. Based on the collected data, the percentage signal difference between enhancing lesion and background (%RS) and signal-difference-to-noise ratio (SDNR) were measured for each lesion. Results The number of lesions detected in the study population was 195. Among all diagnosed lesions, 120 (62%) were assessed to be infiltrating cancers, 16 (8%) non-infiltrating cancers, and 59 (30%) were benign. Thirteen (7%) lesions did not enhance in CESM; all non-enhancing lesions were confirmed to be benign under histopathological examination. Analysis of enhancement indices showed that signal values within lesions and signal values within background ROIs (regions of interest) were similar in CC (craniocaudal) and MLO (mediolateral) projections. Mean %RS values were correlated with the type of enhancing lesion, infiltrating cancers having the highest values, benign lesions the lowest. Conclusions This work has demonstrated a significant correlation between the degree of lesion enhancement in CESM and malignancy. Quantitative analysis of enhancement levels in CESM can distinguish between invasive cancers and benign or in situ lesions. Key Points • There is a possibility of quantitative assessment of contrast enhancement in CESM. • Correlation between quantitative assessment of contrast enhancement in CESM and histopathology was observed.

9 July 2013 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
AAAgnieszka Adamczyk
Agnieszka Adamczyk
JNJoanna A. Niemiec
Joanna A. Niemiec
AAAleksandra Ambicka
Aleksandra Ambicka
AMAnna Mucha-Małecka
Anna Mucha-Małecka
JMJerzy Mituś
Jerzy Mituś
JRJanusz Ryś
Janusz Ryś

28 July 2015 in Polish Journal of Pathology
Verified
Journal Article
Open access
AAAgnieszka Adamczyk
Agnieszka Adamczyk
JNJoanna Niemiec
Joanna Niemiec
AJAnna Janecka
Anna Janecka
AHAgnieszka Harazin-Lechowska
Agnieszka Harazin-Lechowska
AAAleksandra Ambicka
Aleksandra Ambicka
JJJerzy Jakubowicz
Jerzy Jakubowicz
Resistance to trastuzumab in patients with HER2-overexpressing breast cancer is associated with higher risk of progression or cancer death, and might be related to activation of PI3K/AKT/mTOR and Ras/Raf/MAPK signaling cascades and a decreased level of their inhibitor (PTEN). HER2-overexpressing breast cancer patients (n = 75) treated with radical local therapy and trastuzumab in adjuvant setting were included into the study. Deoxyribonucleic acid isolated from paraffin sections was used to assess mutational status of the PIK3CA gene (p.H1047R and p.E545K mutations) by the quantitative polymerase chain reaction technique. Expression of selected proteins (ER, PgR, AR, Ki-67, EGFR) was assessed using immunohistochemistry. In the studied group we found significantly higher Ki-67LI in EGFR-positive carcinomas (p = 0.048). Moreover, EGFR immunonegativity was observed more frequently in low-grade (G1/G2) carcinomas as well as in estrogen/progesterone and androgen receptor immunopositive tumors (p = 0.042, p = 0.016, p = 0.044, respectively). Favorable metastasis-free survival was observed in patients with pN0 and pN1 (vs. pN2+3) stage (p = 0.040) and with tumors characterized by low Ki-67LI (≤ 50% vs. > 50%) (p = 0.014). Patients with tumor androgen receptor immunonegativity (weak or lack of expression) or strong PTEN expression survived 3 years without metastases (p = 0.007). The results of our study suggest that androgen receptor and PTEN status might be considered as indicators of trastuzumab sensitivity.

1 August 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
AAAgnieszka Adamczyk
Agnieszka Adamczyk
AKAnna Kruczak
Anna Kruczak
AHAgnieszka Harazin-Lechowska
Agnieszka Harazin-Lechowska
AAAleksandra Ambicka
Aleksandra Ambicka
AGAleksandra Grela-Wojewoda
Aleksandra Grela-Wojewoda
JNJoanna Niemiec
Joanna Niemiec
Background: The aim of the study was to investigate if parameters associated with human epidermal growth factor receptor type 2 (HER2) status (HER2 gene copy number, HER2/CEP17 ratio or polysomy of chromosome 17) are related to various biological features potentially responsible for trastuzumab resistance (PTEN, IGF-1R, MUC4, EGFR, HER3, HER4, and mutation status of PIK3CA) as well as their influence on survival of HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Patients and methods: The investigated group consisted of 117 patients with invasive ductal breast cancer (T≥1, N≥0, M0) with overexpression of HER2, who underwent radical surgery between 2007 and 2014. Status of ER, PR, and HER2 expression was retrieved from patients’ files. HER2 gene copy number was investigated by fluorescence in situ hybridization using PathVysion HER-2 DNA Probe Kit II. Expression of PTEN, IGF-1R, MUC4, EGFR, HER3, and HER4 was assessed immunohistochemically on formalin-fixed paraffin-embedded tissue sections. PIK3CA mutation status was determined by qPCR analysis. Results: Overexpression of HER2 protein (IHC 3+) and ER negativity corresponded to higher HER2 copy number and HER2/CEP17 ratio (p<0.001). Tumors with polysomy were characterized by higher HER2 gene copy number but lower HER2/CEP17 ratio (p<0.026, p<0.001). Patients with tumors featuring HER3 immunonegativity or low HER2/CEP17 ratio (≤4) were characterized by 100% metastasis-free survival (p=0.018, p=0.062). Conclusion: Presence of both unfavorable factors, ie, HER3 expression and high HER2/CEP17 ratio, allowed to distinguish a group of patients with worse prognosis (p=0.001).

27 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MGMarta Gawin
Marta Gawin
AKAgata Kurczyk
Agata Kurczyk
JNJoanna Niemiec
Joanna Niemiec
ASAgata Stanek-Widera
Agata Stanek-Widera
AGAleksandra Grela-Wojewoda
Aleksandra Grela-Wojewoda
PWPiotr Widlak
Piotr Widlak
Intra-tumor heterogeneity (ITH) results from the coexistence of genetically distinct cancer cell (sub)populations, their phenotypic plasticity, and the presence of heterotypic components of the tumor microenvironment (TME). Here we addressed the potential association between phenotypic ITH revealed by mass spectrometry imaging (MSI) and the prognosis of breast cancer. Tissue specimens resected from 59 patients treated radically due to the locally advanced HER2-positive invasive ductal carcinoma were included in the study. After the on-tissue trypsin digestion of cellular proteins, peptide maps of all cancer regions (about 380,000 spectra in total) were segmented by an unsupervised approach to reveal their intrinsic heterogeneity. A high degree of similarity between spectra was observed, which indicated the relative homogeneity of cancer regions. However, when the number and diversity of the detected clusters of spectra were analyzed, differences between patient groups were observed. It is noteworthy that a higher degree of heterogeneity was found in tumors from patients who remained disease-free during a 5-year follow-up (n = 38) compared to tumors from patients with progressive disease (distant metastases detected during the follow-up, n = 21). Interestingly, such differences were not observed between patients with a different status of regional lymph nodes, cancer grade, or expression of estrogen receptor at the time of the primary treatment. Subsequently, spectral components with different abundance in cancer regions were detected in patients with different outcomes, and their hypothetical identity was established by assignment to measured masses of tryptic peptides identified in corresponding tissue lysates. Such differentiating components were associated with proteins involved in immune regulation and hemostasis. Further, a positive correlation between the level of tumor-infiltrating lymphocytes and heterogeneity revealed by MSI was observed. We postulate that a higher heterogeneity of tumors with a better prognosis could reflect the presence of heterotypic components including infiltrating immune cells, that facilitated the response to treatment.